NCT01857596View on ClinicalTrials.gov

Phase 1b/2a Unblinded Study of Responses in Premenopausal Women With HSDD to Lorexys Evaluating Efficacy and Safety

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Hypoactive Sexual Desire Disorder (DSM-IV-TR Defined)Sexual Interest/Arousal Disorder (DSM-5 Defined)
Interventions
DRUG

bupropion, Lorexys low-dose, Lorexys moderate-dose

Lorexys is a proprietary fixed-dose combination of two agents

Trial Locations (2)

44122

Robert Taylor Segraves, MD, PhD, Beachwood

45219

Molly Katz, MD, Cincinnati

All Listed Sponsors
lead

S1 Biopharma, Inc.

INDUSTRY

NCT01857596 - Phase 1b/2a Unblinded Study of Responses in Premenopausal Women With HSDD to Lorexys Evaluating Efficacy and Safety | Biotech Hunter | Biotech Hunter